Company Description

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.

The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases.

It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.

The company was incorporated in 2005 and is headquartered in Austin, Texas.

XBiotech Inc.

Country	United States
Founded	2005
IPO Date	Apr 15, 2015
Industry	Biotechnology
Sector	Healthcare
Employees	92
CEO	John Simard

Contact Details

Address: 5217 Winnebago Lane Austin, Texas 78744 United States
Phone	512-386-2900
Website	xbiotech.com

Stock Details

Ticker Symbol	XBIT
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001626878
CUSIP Number	98400H102
ISIN Number	CA98400H1029
SIC Code	2834

Key Executives

Name	Position
John Simard	Founder, President, Chief Executive Officer and Chairman
Dr. Sushma Shivaswamy Ph.D.	Chief Scientific Officer
Angela Hu	Director of Finance, Principal Financial and Accounting Officer and Financial Controller

Latest SEC Filings

Date	Type	Title
Jun 20, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
May 1, 2024	ARS	Filing
May 1, 2024	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 1, 2024	DEF 14A	Other definitive proxy statements
May 1, 2024	10-K/A	[Amend] Annual report
Apr 24, 2024	10-K/A	[Amend] Annual report
Mar 15, 2024	10-K	Annual Report
Feb 7, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals

View All SEC Filings